Skip to main content

Table 2 Patient characteristics

From: Antiemetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting

Variable

Granisetron (n = 21)

Palonosetron (n = 18)

p value

Number of patients

21

18

 

Sex

 Male

11

5

0.192

 Female

10

13

 

Age

   

 Median, year (range)

30 (20–55)

31 (25–58)

0.863

Age (years)

   

  ≥ 35

8

8

0.752

  < 35

13

10

 

ECOG-PSa score

 0

20

16

0.586

 1

1

2

 

Combined antiemetics

 None

6

5

0.633

 Corticosteroidb

0

2

 

 Aprepitant

9

7

 

 Corticosteroid + Aprepitant

6

4

 
  1. aECOG-PS, Eastern Cooperative Oncology Group performance status
  2. bCorticosteroids included dexamethasone or hydrocortisone